AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Overactive Bladder (OAB): Darifenacin hydrobromide is a type of medication known as an antimuscarinic or anticholinergic agent. It works by blocking the action of acetylcholine, a neurotransmitter involved in bladder muscle contractions. By reducing bladder muscle contractions, darifenacin helps to decrease the symptoms of overactive bladder, including urinary urgency, frequency, and urge incontinence.
Improvement of Urinary Symptoms: Darifenacin hydrobromide helps improve urinary symptoms associated with overactive bladder, such as the sudden and frequent urge to urinate, as well as episodes of urinary leakage (urge incontinence). By reducing bladder muscle contractions and increasing bladder capacity, darifenacin can help individuals regain control over their bladder function and improve their quality of life.
Side Effects: Like other medications in its class, darifenacin hydrobromide may cause certain side effects, including dry mouth, constipation, blurred vision, and difficulty urinating. Additionally, some individuals may experience cognitive issues such as confusion, memory impairment, or difficulty concentrating while taking darifenacin. These cognitive side effects are more common in elderly individuals or those with preexisting cognitive impairment.
Risk of Cognitive Issues: Darifenacin hydrobromide, like other antimuscarinic medications, has the potential to cause cognitive issues due to its effects on the central nervous system. Antimuscarinic agents can cross the blood-brain barrier and affect cognitive function, particularly in susceptible individuals. Older adults are at higher risk of experiencing cognitive side effects due to age-related changes in drug metabolism and increased sensitivity to anticholinergic medications.
Monitoring and Management: Healthcare providers prescribing darifenacin hydrobromide should carefully consider the potential risks and benefits, particularly in elderly patients or those with cognitive impairment. Regular monitoring of cognitive function and close communication with patients and caregivers are essential to detect and manage any cognitive issues that may arise during treatment with darifenacin hydrobromide.
Individualized Treatment Approach: When prescribing darifenacin hydrobromide, healthcare providers should take into account the patient's medical history, concomitant medications, cognitive status, and overall health status. In some cases, alternative treatment options may be considered for individuals at higher risk of cognitive side effects, such as behavioral therapies, lifestyle modifications, or other pharmacological treatments with a lower risk of cognitive impairment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.5 | 0 |
| Allergies | 0 | 0.9 | 0 |
| Allergy to milk products | 0 | 0 | |
| Alzheimer's disease | 0 | 1.9 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0 | 0 |
| Ankylosing spondylitis | 0.9 | 0 | 0 |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Asthma | 0.1 | 0.1 | |
| Atherosclerosis | 0 | 0 | |
| Atrial fibrillation | 0.9 | 0.9 | 0 |
| Autism | 1.7 | 2.6 | -0.53 |
| Bipolar Disorder | 0 | 0.5 | 0 |
| Carcinoma | 0 | 0 | 0 |
| Celiac Disease | 0.3 | 0 | 0 |
| Cerebral Palsy | 0 | 0 | |
| Chronic Fatigue Syndrome | 0.3 | 1.5 | -4 |
| Chronic Kidney Disease | 0 | 1.4 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | -0.4 | |
| Chronic Urticaria (Hives) | 0.9 | -0.9 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0 | |
| Colorectal Cancer | 0 | 0.5 | 0 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.5 | 0.4 | 0.25 |
| COVID-19 | 0.1 | 3.2 | -31 |
| Crohn's Disease | 0.5 | 1.4 | -1.8 |
| deep vein thrombosis | 0 | 0 | |
| Depression | 0.6 | 2.9 | -3.83 |
| Endometriosis | 0.4 | 0 | 0 |
| Fibromyalgia | 1.7 | -1.7 | |
| Functional constipation / chronic idiopathic constipation | 0.3 | 1.3 | -3.33 |
| gallstone disease (gsd) | 0 | 0 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.4 | -0.4 | |
| Gout | 0.4 | -0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | 0.5 | 0.2 |
| hypertension (High Blood Pressure | 0 | 0.4 | 0 |
| Hypothyroidism | 0.5 | -0.5 | |
| IgA nephropathy (IgAN) | 0.9 | -0.9 | |
| Inflammatory Bowel Disease | 0 | 2.8 | 0 |
| Intelligence | 0.4 | 0.9 | -1.25 |
| Intracranial aneurysms | 0 | 0 | |
| Irritable Bowel Syndrome | 0 | 0.3 | 0 |
| Liver Cirrhosis | 0.4 | 0.4 | 0 |
| Long COVID | 1.7 | 0.9 | 0.89 |
| Low bone mineral density | 0.4 | -0.4 | |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0.8 | -0.8 | |
| ME/CFS without IBS | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.5 | 0.7 | -0.4 |
| Mood Disorders | 1.1 | 3 | -1.73 |
| Multiple Sclerosis | 0.1 | 1.9 | -18 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 1.4 | -0.56 |
| Obesity | 0.4 | 0.6 | -0.5 |
| obsessive-compulsive disorder | 0.3 | 1.8 | -5 |
| Osteoarthritis | 0 | 0 | |
| Osteoporosis | 0 | 0 | |
| Parkinson's Disease | 0.5 | 0.9 | -0.8 |
| Polycystic ovary syndrome | 0.3 | 0 | 0 |
| Postural orthostatic tachycardia syndrome | 0.4 | -0.4 | |
| Psoriasis | 0 | 1.3 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 0.4 | 2.5 |
| Rosacea | 0 | 0 | |
| Schizophrenia | 0.5 | 0.4 | 0.25 |
| scoliosis | 0.4 | 0 | 0 |
| Sjögren syndrome | 0.9 | 0.5 | 0.8 |
| Sleep Apnea | 0.4 | 0.5 | -0.25 |
| Stress / posttraumatic stress disorder | 0.5 | -0.5 | |
| Systemic Lupus Erythematosus | 0.5 | 0 | 0 |
| Tic Disorder | 0.3 | 0.9 | -2 |
| Type 1 Diabetes | 0.7 | 0.3 | 1.33 |
| Type 2 Diabetes | 0.7 | 0.7 | 0 |
| Ulcerative colitis | 0.1 | 1.6 | -15 |
| Unhealthy Ageing | 0.7 | 1.4 | -1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.